EMA Adopts a Positive Opinion for a New Route of Administration Together with a New Pharmaceutical Form and a New Strength for Isatuximab By Ogkologos - May 8, 2026 61 0 Facebook Twitter Google+ Pinterest WhatsApp It is a cancer medicine used to treat adult patients with multiple myeloma Source RELATED ARTICLESMORE FROM AUTHOR ESMO Joins WHO Global Clinical Trials Forum to Strengthen Global Oncology Research Ecosystems EMA Recommends Extension of Therapeutic Indications for Enfortumab Vedotin Selinexor plus Ruxolitinib Reduces Spleen Volume, but Does Not Improve Symptom Responses Over Ruxolitinib in Patients with JAK Inhibitor-Naïve Myelofibrosis MOST POPULAR Adjuvant Alectinib Significantly Improves Disease-Free Survival in Patients with Resected ALK-positive... April 18, 2024 Stem cell research: meet the scientist growing ‘mini guts’ in her... April 8, 2022 What Do “Health Equity” and “Quality Care” Mean in Cancer Care? December 20, 2022 Survey Shows Oncologists Underestimate How Many Cancer Patients Use Alternative Therapies June 16, 2021 Load more HOT NEWS 2023 ASCO Annual Meeting Research Round Up: Progress in Treating Breast... New hormone treatment for advanced prostate cancer made available in England ‘Jeopardy!’ Legend James Holzhauer Donates Portion Of Winnings To Cancer Walk... Study Suggests a Link between Stress and Cancer Coming Back
